Bluejay is dedicated to developing potentially life-changing therapeutics for patients with serious viral and liver diseases.
Our pipeline of clinically differentiated assets includes lead asset brelovitug (BJT-778), a high potency, fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) of the hepatitis B virus.
Our lead asset brelovitug (BJT-778) is a high potency, fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) of the hepatitis B virus with pan-genotypic activity. It is being investigated as a potential monotherapy for adults with chronic hepatitis D and as the foundation of a combination strategy for the functional cure of chronic hepatitis B. Brelovitug neutralizes and removes hepatitis B and hepatitis D virions and depletes HBsAg-containing subviral particles. In addition, brelovitug has shown it has the potential to be a potent immunomodulator.
Brelovitug has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, as well as Orphan and PRIME designation from the European Medicines Agency.
Our phase 3 program for brelovitug has begun with our first patient dosed in the AZURE-1 trial in March 2025. Please see more information on the trial here.
Cavrotolimod is a proprietary spherical toll-like receptor 9 (TLR9) agonist oligonucleotide designed to activate both innate and adaptive immune responses. It is being investigated for its potential to enhance antiviral immunity in patients with chronic hepatitis B and improve the functional cure rate for CHB as a part of combination regimens.
BJT-628 is an orally bioavailable, liver-targeted HBV transcript inhibitor believed to stabilize HBV messenger RNA transcripts. In preclinical studies, BJT-628 demonstrated a significant reduction in hepatitis B surface antigen (HBsAg) levels. We believe this approach complements the mechanism of action of brelovitug, and that combining brelovitug with BJT-628 may further reduce HBsAg levels.
BJT-628 is the first product candidate developed using Bluejay’s Liver-Targeting Advanced Platform (L-TAP), which is designed to enable selective delivery of drug to the liver to help optimize both potency and safety.
BJT-188 is a liver-targeted fatty acid synthase (FASN) inhibitor being investigated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Preclinical data on BJT-188 showed potent FASN inhibition with high liver tissue distribution specificity. BJT-188 was developed using Bluejay’s Liver-Targeting Advanced Platform (L-TAP), which is designed to enable selective delivery of drug to the liver to help optimize both potency and safety.
Bluejay Therapeutics’ Liver-Targeting Advanced Platform (L-TAP) has the potential to create novel therapeutics for liver diseases.
L-TAP optimizes the benefit/risk profile of small molecules through precise targeting of specific liver cell types associated with disease, potentially improving:
A global, randomized, controlled Phase 2b/3 pivotal study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (BJT-778) as monotherapy for chronic hepatitis D (CHD). This study is being conducted in the United States and other countries around the world.
Learn more at clinicaltrials.gov.
Expanded Access is a potential pathway for patients with immediately life-threatening diseases or conditions to obtain investigational products outside of a clinical trial.
Dr. Keting Chu is an experienced biotech executive, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture investments.
Prior to founding Bluejay, Keting was a Partner and a Venture partner at LYFE Capital. Working with the team in Lyfe capital, Keting helped to close $550M Lyfe Capital Fund III and invested in Ansun Biopharm, Pliant Therapeutics and Tempest Therapeutics. Pliant and Tempest went IPO in NASDAQ successfully in 2020 and 2021. Keting was previously a venture partner in Apple Tree Partners briefly. Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS). There she was responsible for venture philanthropy, also known as the Therapy Acceleration program. At LLS, Keting led the investment into Celator, Stemline, Constellation, Affimed, ArgenX, Kite Pharma, Kiadis, OncoPep, Valor and a number of projects in academic institutions with the focus on proof-of-concept (POC) studies in patients. Three of the nine companies received “Breakthrough” designation by the FDA in 2016 after positive proof-of-concept studies. Celator was acquired by Jazz Pharma for $1.5B, Kite by Gilead for $12B and Stemline by Menarini for $677M. Three NDAs, by Celator, Kite and Stemline, were approved by the US FDA successfully. Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc. and BioCubed Corporation. For her first startup company, Five Prime Therapeutics, Keting was Vice President of Biology and Head of R&D where she built the R&D strategy and team, established the technology platform and generated a product pipeline. Prior to Five Prime, Keting was the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical and clinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases. Three cancer therapeutic antibodies that keting led the team from discovery to phase I clinical trials are in phase II and III testing now.
Keting received her MD in Sun Yat-Sen Medical University where she specialized in infectious diseases in China, and Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF). She also conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.